Small cell lung cancer patients receiving focused treatment lived a median of 17 months compared to nine months with whole brain radiation.
RT’s Three Key Takeaways
- Survival Advantage: Patients with small cell lung cancer and brain metastases lived a median of 17.4 months after receiving stereotactic radiosurgery compared with 8.6 months after hippocampal-avoidant whole brain radiation therapy, according to clinical trial findings presented at the American Society for Radiation Oncology annual meeting.
- Cognitive Preservation: The randomized phase 3 study revealed no statistically significant differences between the two treatment approaches regarding time to cognitive decline, neurologic death, or serious treatment-related side effects.
- Practice Implications: The results provide randomized evidence supporting focused radiosurgery as an alternative to whole brain irradiation for appropriately selected patients, challenging historical standards of care.
Patients with small cell lung cancer (SCLC) that had spread to the brain lived a median of 17 months following focused stereotactic radiosurgery (SRS), compared with nine months after an advanced form of whole brain radiation therapy (WBRT), according to data from a randomized phase 3 clinical trial presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
For decades, SCLC has remained an exception to the broader oncology shift toward focused radiation for secondary brain tumors because of concerns that treating only visible lesions could leave microscopic cancer unchecked throughout the brain. While the trial found that SRS did not meet its primary endpoint of delaying the time to neurocognitive decline, investigators observed no significant differences between the cohorts in neurologic death or severe treatment-related side effects.
“Although stereotactic radiosurgery is the preferred treatment for brain metastases caused by most other tumors, small cell lung cancer has been an exception where whole brain radiotherapy has remained standard of care,” said Chad Rusthoven, MD, co-principal investigator of the trial and a radiation oncologist at the University of Colorado Anschutz School of Medicine\. “Our findings suggest that patients can now have a more individualized discussion about whether focused radiosurgery or whole brain treatment is right for them.”
Comparing Modern Radiation Strategies
Brain metastases occur when primary cancer cells disseminate through the vascular system to the brain, presenting complex clinical challenges for multidisciplinary oncology and respiratory healthcare teams. SRS delivers high-dose radiation directly to individual lesions while sparing adjacent healthy brain tissue, whereas WBRT targets the whole brain to treat both visible metastases and microscopic seedings.
Prior randomized studies confirmed the cognitive and quality-of-life benefits of SRS in several solid tumors, yet patients with SCLC were historically excluded from those evaluations. In response, the NRG-CC009 trial compared SRS against an advanced cognitive-sparing standard: hippocampal-avoidant whole brain radiation therapy (HA-WBRT) combined with memantine, a neuroprotective pharmaceutical.
“Advances in radiation therapy have fundamentally changed the options for patients with brain metastases,” said Vinai Gondi, MD, lead principal investigator of the trial and director of radiation oncology at the Northwestern Medicine West Region and Proton Center. “NRG-CC009 reflects how far both approaches have come. For patients with small cell lung cancer, we now have two modern radiation therapy strategies to consider and randomized evidence to help us understand how best to use them.”
Key Trial Findings and Survival Data
Between 2021 and 2026, the NRG-CC009 study randomized 151 patients with SCLC and brain metastases to receive either SRS or HA-WBRT with memantine. Participants presented with brain metastases measuring no larger than 4 centimeters and a total tumor burden no greater than 30 cubic centimeters, with a median of two metastases per patient.
On the primary endpoint of time to cognitive decline evaluated through standardized cognitive assessments, researchers documented no significant variance between the two arms. Investigators noted that the cognitive-sparing nature of HA-WBRT and memantine in the control arm likely narrowed the measurable difference between therapies.
However, median overall survival reached 17.4 months in the SRS arm versus 8.6 months in the HA-WBRT cohort. After adjusting for patient and disease characteristics, SRS corresponded to a 40% reduction in the risk of death, though Rusthoven emphasized that overall survival was a prespecified secondary endpoint for which the study was not primarily powered.
“At this point, we need to be cautious about assigning a specific cause to the observed differences in survival,” said Rusthoven, co-principal investigator of the trial and a radiation oncologist at the University of Colorado Anschutz School of Medicine, in a news release. “The baseline prognostic factors were well balanced between the treatment arms, but there is always a possibility of imbalances in unmeasured variables. It is also possible that SRS and HA-WBRT may have differential downstream effects on the disease course that affect survival. Further investigation into these areas is needed.”
The trial also found no significant differences between cohorts in deaths resulting from neurologic causes. While crude rates of central nervous system (CNS) disease progression were lower with HA-WBRT, the difference was not statistically significant after adjusting for baseline characteristics.
“Although no differences were observed in neurocognitive function between the treatment arms, the improved survival with SRS addresses a fundamental historical concern with SCLC – that omission of WBRT might lead to worse survival,” said Gondi. “Overall, these results support SRS as a reasonable option for patients with brain metastases from SCLC.”
Informing Clinical Decisions in Thoracic Oncology
For healthcare providers managing advanced thoracic malignancies, the trial offers valuable prospective data to help guide shared decision-making.
“Patients with small cell lung cancer have largely been left out of the randomized trials that established radiosurgery as a standard treatment for patients with brain metastases. This study begins to close that evidence gap and gives clinicians much greater confidence that focused treatment can be a reasonable option for appropriately selected patients. The long-term goal is to give each patient the treatment that best fits their disease and priorities rather than defaulting to one approach based on diagnosis alone,” said Charles B Simone II, MD, chair of ASTRO’s lung cancer resource panel and a radiation oncologist at New York Proton Center and Memorial Sloan Kettering Cancer Center.
